What will become of the German antidiabetics market?
This article was originally published in Scrip
Yet another company – this time Novo Nordisk – has decided that it wouldn't be good business to sell its antidiabetic in Germany following a rocky ride through the AMNOG benefit assessment and pricing negotiations. While companies are worried about the future of treatments for chronic diseases in Germany, prescribers and health insurers are more sanguine and believe that German patients are not yet missing out on important innovations in the market.
You may also be interested in...
But Novo Nordisk CEO says a DEVOTE-based efficacy price review in Germany analyzing patient sub-groups 'will be a lengthy process'.
Germany’s health technology appraisal institute, IQWiG, says that oncology drugs take up more of its time than treatments for any other conditions. And while it welcomes advances in immuno-oncology, it wants to see breakthroughs in other disease areas too.
Under forthcoming changes to the law, companies could gain confidential pricing in Germany, which could make it easier to defend a higher price in other countries. But sponsor of some orphan products may face a rockier path to market.